Literature DB >> 689737

Interaction of inflammatory cells and oral microorganisms. VII. In vitro polymorphonuclear responses to viable bacteria and to subcellular components of avirulent and virulent strains of Actinomyces viscosus.

N S Taichman, B F Hammond, C C Tsai, P C Baehni, W P McArthur.   

Abstract

Both virulent (V) and avirulent (AV) strains of Actinomyces viscosus T14 are capable of colonizing the oral cavity of gnotobiotic rats, but only T14-V causes destructive periodontal disease. The basis for this difference in in vivo pathogenicity has not been adequately defined. In the present study we compared the capacities of T14-AV and T14-V to provoke in vitro extracellular release of lysosomal constituents from human polymorphonuclear leukocytes (PMNs). In serum-free cultures, viable T14-V but not T14-AV stimulated discharge of PMN lysosomes. The release response was correlated with PMN phagocytic activity; thus, PMNs readily ingested T14-V but not T14-AV. To explain these differences in PMN-bacteria interactions, subcellular fractions of T14-AV or T14-V were incubated with PMNs. A crude, insoluble sonic extract derived from T14-V caused PMN lysosome release, but a similar fraction from T14-AV was inactive. However, following extensive washing and treatment with deoxyribonuclease or sodium dodecyl sulfate, cell wall fractions of T14-AV stimulated lysosome release. These procedures apparently removed an extracellular polysaccharide slime which is synthesized by T14-AV but not by T14-V. There was a significant reduction in the capacities of viable T14-V or cell wall fractions of T14-V or T14-AV to provoke PMN lysosome release when these agents were preincubated with a slime material isolated from T14-AV. This inhibitory influence of slime was overcome by the addition of fresh or heated (56 degrees C, 30 min) serum to the PMN-bacteria cultures. The data suggest a relationship between the abilities of the avirulent and virulent strains of A. viscosus T14 to act as periodontal pathogens in vivo and to serve as stimuli for PMN lysosome release in vitro.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 689737      PMCID: PMC422035          DOI: 10.1128/iai.21.2.594-604.1978

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  33 in total

1.  Activation of the complement system by some gram-positive oral bacteria.

Authors:  C C Tsai; U R Nilsson; W P McArthur; N S Taichman
Journal:  Arch Oral Biol       Date:  1977       Impact factor: 2.633

2.  Electron microscopic study of the interaction of oral microorganisms with polymorphonuclear leukocytes.

Authors:  P Baehni; M A Listgarten; N S Taichman; W P McArthur
Journal:  Arch Oral Biol       Date:  1977       Impact factor: 2.633

Review 3.  Microbiology of periodontal disease -- present status and future considerations.

Authors:  S S Socransky
Journal:  J Periodontol       Date:  1977-09       Impact factor: 6.993

4.  Biological activity of fragments derived from the extracellular slime glycolipoprotein of Pseudomonas aeruginosa.

Authors:  J W Sensakovic; P F Bartell
Journal:  Infect Immun       Date:  1975-10       Impact factor: 3.441

5.  Non-encapsulated variant of Cryptococcus neoformans. II. Surface receptors for cryptococcal polysaccharide and their role in inhibition of phagocytosis by polysaccharide.

Authors:  T R Kozel
Journal:  Infect Immun       Date:  1977-04       Impact factor: 3.441

6.  Morphological features and functional properties of human fibroblasts exposed to Actinomyces viscosus substances.

Authors:  D Engel; H E Schroeder; R C Page
Journal:  Infect Immun       Date:  1978-01       Impact factor: 3.441

7.  Interaction of inflammatory cells and oral microorganisms. IV. In vitro release of lysosomal constituents from polymorphonuclear leukocytes exposed to supragingival and subgingival bacterial plaque.

Authors:  N S Taichman; C C Tsai; P C Baehni; N Stoller; W P McArthur
Journal:  Infect Immun       Date:  1977-06       Impact factor: 3.441

8.  Cytotoxicity of rat macrophages activated by persistent or biodegradable bacterial cell walls.

Authors:  R J Smialowicz; J H Schwab
Journal:  Infect Immun       Date:  1977-09       Impact factor: 3.441

9.  In vivo distribution of Pseudomonas aeruginosa slime glycolipoprotein: association with leukocytes.

Authors:  M Lynn; J W Sensakovic; P F Bartell
Journal:  Infect Immun       Date:  1977-01       Impact factor: 3.441

10.  Arthritis in rats after systemic injection of streptococcal cells or cell walls.

Authors:  W J Cromartie; J G Craddock; J H Schwab; S K Anderle; C H Yang
Journal:  J Exp Med       Date:  1977-12-01       Impact factor: 14.307

View more
  6 in total

1.  Modulation of bacterial aggregation by PMN and platelet extracts.

Authors:  D Malamud; R Goldman; N S Taichman
Journal:  Inflammation       Date:  1983-06       Impact factor: 4.092

2.  Comparative histopathology of lesions produced by Actinomyces israelii, Actinomyces naeslundii, and Actinomyces viscosus in mice.

Authors:  M J Behbehani; J D Heeley; H V Jordan
Journal:  Am J Pathol       Date:  1983-03       Impact factor: 4.307

3.  Sialidase-enhanced lectin-like mechanism for Actinomyces viscosus and Actinomyces naeslundii hemagglutination.

Authors:  R P Ellen; E D Fillery; K H Chan; D A Grove
Journal:  Infect Immun       Date:  1980-02       Impact factor: 3.441

4.  Biochemical and morphological characterization of the killing of human monocytes by a leukotoxin derived from Actinobacillus actinomycetemcomitans.

Authors:  N S Taichman; R T Dean; C J Sanderson
Journal:  Infect Immun       Date:  1980-04       Impact factor: 3.441

5.  Selective antibacterial properties of lysozyme for oral microorganisms.

Authors:  V J Iacono; B J MacKay; S DiRienzo; J J Pollock
Journal:  Infect Immun       Date:  1980-08       Impact factor: 3.441

6.  Leukotoxicity of an extract from Actinobacillus actinomycetemcomitans for human gingival polymorphonuclear leukocytes.

Authors:  N S Taichman; J M Wilton
Journal:  Inflammation       Date:  1981-03       Impact factor: 4.092

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.